<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604834</url>
  </required_header>
  <id_info>
    <org_study_id>OF14-004</org_study_id>
    <nct_id>NCT04604834</nct_id>
  </id_info>
  <brief_title>Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy</brief_title>
  <official_title>Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Nuevo Leon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Autonoma de Nuevo Leon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotrophic keratopathy (NK) is a condition where the cornea loses its capacity to feel pain&#xD;
      and touch. This causes a decrease in the production of certain substances that maintain the&#xD;
      integrity of the corneal epithelium (the most superficial layer that covers the cornea). As a&#xD;
      result, the cornea cannot heal wounds as fast as it should and this could lead to corneal&#xD;
      breakdown. This disease is chronic, meaning that it does not resolve quickly, and the&#xD;
      treatments commonly used to manage it (such as artificial tears) take a long time to work,&#xD;
      which makes it hard to follow doctor's orders. Autologous platelet-rich plasma is a substance&#xD;
      that is obtained from the patient's own blood and it may contain those components that are&#xD;
      missing in the tears of people with NK. The purpose of this experiment is to find out whether&#xD;
      APRP+PFAT is better than APRP alone or PFAT alone in the treatment of NK. Participants will&#xD;
      be randomly assigned to one of three groups: one group will start with APRP, other will start&#xD;
      with PFAT and another with PFAT+APRP. The participants will receive each treatment for four&#xD;
      weeks, and then the subjects will switch groups and use them for four weeks each (12 weeks&#xD;
      total). Investigators will evaluate different parameters that will let us know if your&#xD;
      condition is improving. These evaluations will be carried out every four weeks from the start&#xD;
      to the end of the protocol. In case of intolerance or adverse effects, treatment will be&#xD;
      discontinued.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurotrophic keratopathy is characterized by impaired corneal sensitivity that results in a&#xD;
      decrease in neurotrophic and epitheliotropic factors that are essential for proper corneal&#xD;
      epithelial and ocular surface function. This neurotrophic state halts mitosis and epithelial&#xD;
      turnover, which in turn slow down wound healing and lead to epithelial breakdown. Due to the&#xD;
      chronicity of this disease, treatment adherence becomes a problem for patients; furthermore,&#xD;
      results with conventional treatments such as preservative-free artificial tears are&#xD;
      discouraging. Hematopoietic derivatives such as APRP may replace those missing neurotrophic&#xD;
      factors and lead to epithelial healing in a faster and more comfortable manner. The objective&#xD;
      of this study is to determine if APRP+PFAT is better than autologous platelet-rich plasma&#xD;
      (APRP) or preservative-free artificial tears (PFAT) in the treatment of neurotrophic&#xD;
      keratopathy. Subjects will be randomly assigned to one of three groups and treatment will be&#xD;
      administered for four weeks. After this period, subjects will switch groups and receive the&#xD;
      new treatment for four more weeks (cross-over). After this second period is completed,&#xD;
      subjects will receive the last treatment for four more weeks. A thorough ophthalmologic&#xD;
      evaluation will be performed before starting treatment and every four weeks until completion.&#xD;
      Treatment will be discontinued if there are adverse effects or treatment intolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be selected based on inclusion and exclusion criteria. A thorough ophthalmologic evaluation will be carried out before starting any treatment (baseline). Subjects will be randomly assigned to one of the treatment groups and receive the corresponding treatment for 4 weeks. At the end of week 4, subjects will switch treatment groups (crossover) and receive the new treatment for 4 more weeks. At the end of week 8, subjects will start the last treatment for 4 more weeks. Ophthalmologic evaluations will be performed every 4 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No blinded study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in corneal staining</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Change in corneal epithelial damage will be measured using corneal staining with fluorescein dye and the NEI grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in corneal sensitivity</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Change in corneal sensitivity will be measured using Cochet-Bonnet aesthesiometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear break-up time (TBUT)</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Tear break up time will be assessed using fluorescein dye, measuring break up time in seconds. A result &gt;10 seconds will be considered normal, a result &lt;10 seconds will be considered pathological.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Ocular surface symptoms will be assessed by the Ocular Surface Disease Index (OSDI). The OSDI questionnaire consists of 12 questions that assess dry eye symptoms and their effects on vision related function. The questionnaire is divided in 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients are asked to rate their responses on a 0 to 4 scale where 0 represents &quot;none of the time&quot;, 1 &quot;some of the time&quot;, 2 &quot;half of the time&quot;, 3 &quot;most of the time&quot;, and 4 &quot;all of the time&quot;. The total score is calculated using the following formula: ([sum of scores for all questions answered x 100] / [total number of questions answered x 4]). Lower scores represent a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear osmolarity.</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Tear osmolarity is one of tear inflammation biomarkers. Tear osmolarity will be performed with Tear Lab Osmolarity System, a result of 308 milliosmol (mOsm)/L or higher indicates pathological result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer test with anesthesia</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Tear production will be measured by Schirmer test with anesthesia. The Schirmer test with anesthesia &gt;15 mm is consider normal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life questionnaire (National Eye Institute Visual Function Questionnaire-25)</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Quality of life as assessed by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). The NEI VFQ-25 questionnaire consists of 25 questions that assess the effect of visual impairment on the patient's quality of life. The 25-item questionnaire gives a score on a scale of 0 to 100, where 0 is the worst score and 100 is the best score. Higher scores represent a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Best corrected visual acuity will be assessed using Snellen cards. Measurements will be converted to LogMar values for statistical analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events.</measure>
    <time_frame>from the beginning of the treatment and every 4 weeks until week 12.</time_frame>
    <description>Frequency of adverse events will assessed for security and effectiveness of the treatment during the ophthalmic evaluation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Neurotrophic Keratopathy</condition>
  <arm_group>
    <arm_group_label>PFAT first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 eyedrop of PFAT every 2 hours in study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APRP first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 eyedrop of APRP every 2 hours in study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APRP+PFAT first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 eyedrop of PFAT and APRP every 2 hours in study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PFAT first</intervention_name>
    <description>Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.</description>
    <arm_group_label>APRP+PFAT first</arm_group_label>
    <arm_group_label>PFAT first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>APRP first</intervention_name>
    <description>Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.</description>
    <arm_group_label>APRP first</arm_group_label>
    <arm_group_label>APRP+PFAT first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  Neurotrophic keratopathy diagnosed by esthesiometry (defined as central corneal&#xD;
                  sensitivity â‰¤ 3cm using Cochet-Bonnet aesthesiometer).&#xD;
&#xD;
               -  Corneal erosions.&#xD;
&#xD;
               -  Neurotrophic keratopathy secondary to: diabetes mellitus, herpetic keratitis,&#xD;
                  microbial keratitis sequelae (bacteria, Acanthamoeba, fungi, herpes), limbal stem&#xD;
                  cell deficiency, chemical or thermic burn sequelae at least 3 months after the&#xD;
                  accident, ocular trauma with penetrating wound fixed at least 3 months before the&#xD;
                  trial, surgery carried out at least 3 month before the trial (including&#xD;
                  keratoplasty, laser in situ keratomileusis, phacoemulsification cataract surgery,&#xD;
                  extracapsular cataract extraction), adenoviral keratoconjunctivitis resolved at&#xD;
                  least 3 months the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with:&#xD;
&#xD;
               -  Other ocular surface pathology presenting with corneal erosions but without&#xD;
                  corneal hyposensitivity.&#xD;
&#xD;
               -  Corneal epithelial defect with or without corneal hyposensitivity.&#xD;
&#xD;
          -  Pregnant women, homeless, migrants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Mohamed-Noriega, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Oftalmologia, Hospital Universitario Dr. Jose Eleuterio Gonzalez</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim Mohamed-Noriega, M.D.</last_name>
    <phone>+52 8183469259</phone>
    <email>karim.mohamednrg@uanl.edu.mx,drkmohamed1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Departamento de Oftalmologia, Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Mohamed-Noriega, M.D.</last_name>
      <phone>+52 81 83469259</phone>
      <email>karim.mohamednrg@uanl.edu.mx, drkmohamed1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Karim Mohamed-Noriega, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Nuevo Leon</investigator_affiliation>
    <investigator_full_name>Karim Mohamed-Noriega</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Autologous PRP</keyword>
  <keyword>Neurotrophic keratopathy</keyword>
  <keyword>Autologous platelet-rich plasma</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

